L. V. Saprykina, M. R. Narimanova, D. M. Ibragimova
{"title":"含螺环酮联合口服避孕药对多囊卵巢综合征女性人体测量、超声特征及碳水化合物代谢参数的影响","authors":"L. V. Saprykina, M. R. Narimanova, D. M. Ibragimova","doi":"10.32364/2618-8430-2022-5-2-118-121","DOIUrl":null,"url":null,"abstract":"Background: polycystic ovary syndrome (PCOS) is an endocrine disorder affecting 10% of women of reproductive age. Combined oral contraceptive pills (COCP) are effective in PCOS. Drospirenone is a new progestin with properties similar to natural progesterone (including anti-mineralocorticoid and antiandrogenic activities). Aim: to evaluate the effect of drospirenone-containing COCP (20 μg ethinylestradiol and 3 mg drospirenone) on anthropometric and sonographic characteristics, and carbohydrate metabolism parameters in women with PCOS. Patients and Methods: this prospective study enrolled 22 women of reproductive age (mean age 22.1±0.5 years) with PCOS. All females were treated during six cycles (28 days each). At baseline and 6 months after starting treatment, anthropometric (body mass index/BMI, waist-to- hip ratio/WHR) and sonographic (ovary volume) characteristics, and carbohydrate metabolism parameters (plasma insulin, fasting glucose, homeostasis model assessment of insulin resistance/HOMA-IR) were assessed. Results: 6 months after starting treatment, a significant (p<0.05) reduction in BMI (from 22.54±0.43 kg/m2 to 20.86±0.26 kg/m2), WHR (from 0.81±0.01 to 0.78±0.01), and ovary volume (left ovary: from 12.75±0.43 cm3 to 8.05±0.15 cm3; right ovary: from 13.0±0.54 cm3 to 8.63±0.14 cm3) was reported. Meanwhile, no significant (р>0.05) changes in plasma insulin concentration (9.91±0.42 μU/ml vs. 9.52±0.31 μU/ml), fasting blood glucose (4.95±0.08 mmol/l vs. 4.9±0.07 mmol/l), and HOMA-IR (3.2±1.12 vs. 3.06±0.07) compared to baseline levels were reported. The most common side effects were headache or dizziness (n=3, 13.6%), nausea (n=2, 9.1%) and irregular bleeding (n=3, 13.6%). Conclusion: drospirenone-containing COCP has a beneficial effect on anthropometric paramaters and ovary volume but does not affect carbohydrate metabolism. This drug is characterized by excellent compliance. KEYWORDS: polycystic ovary syndrome, drospirenone, body mass index, waist-hip ratio, reproductive age, ovary volume, glucose, insulin, carbohydrates, HOMA-IR. FOR CITATION: Saprykina L.V., Narimanova M.R., Ibragimova D.M. Effect of drospirenone-containing combined oral contraceptive pills on anthropometric and sonographic characteristics and carbohydrate metabolism parameters in women with polycystic ovary syndrome. Russian Journal of Woman and Child Health. 2022;5(2):118–121 (in Russ.). DOI: 10.32364/2618-8430-2022-5-2-118-121.","PeriodicalId":34075,"journal":{"name":"RMZh Mat'' i ditia","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effect of drospirenone-containing combined oral contraceptive pills on anthropometric and sonographic characteristics and carbohydrate metabolism parameters in women with polycystic ovary syndrome\",\"authors\":\"L. V. Saprykina, M. R. Narimanova, D. M. Ibragimova\",\"doi\":\"10.32364/2618-8430-2022-5-2-118-121\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: polycystic ovary syndrome (PCOS) is an endocrine disorder affecting 10% of women of reproductive age. Combined oral contraceptive pills (COCP) are effective in PCOS. Drospirenone is a new progestin with properties similar to natural progesterone (including anti-mineralocorticoid and antiandrogenic activities). Aim: to evaluate the effect of drospirenone-containing COCP (20 μg ethinylestradiol and 3 mg drospirenone) on anthropometric and sonographic characteristics, and carbohydrate metabolism parameters in women with PCOS. Patients and Methods: this prospective study enrolled 22 women of reproductive age (mean age 22.1±0.5 years) with PCOS. All females were treated during six cycles (28 days each). At baseline and 6 months after starting treatment, anthropometric (body mass index/BMI, waist-to- hip ratio/WHR) and sonographic (ovary volume) characteristics, and carbohydrate metabolism parameters (plasma insulin, fasting glucose, homeostasis model assessment of insulin resistance/HOMA-IR) were assessed. Results: 6 months after starting treatment, a significant (p<0.05) reduction in BMI (from 22.54±0.43 kg/m2 to 20.86±0.26 kg/m2), WHR (from 0.81±0.01 to 0.78±0.01), and ovary volume (left ovary: from 12.75±0.43 cm3 to 8.05±0.15 cm3; right ovary: from 13.0±0.54 cm3 to 8.63±0.14 cm3) was reported. Meanwhile, no significant (р>0.05) changes in plasma insulin concentration (9.91±0.42 μU/ml vs. 9.52±0.31 μU/ml), fasting blood glucose (4.95±0.08 mmol/l vs. 4.9±0.07 mmol/l), and HOMA-IR (3.2±1.12 vs. 3.06±0.07) compared to baseline levels were reported. The most common side effects were headache or dizziness (n=3, 13.6%), nausea (n=2, 9.1%) and irregular bleeding (n=3, 13.6%). Conclusion: drospirenone-containing COCP has a beneficial effect on anthropometric paramaters and ovary volume but does not affect carbohydrate metabolism. This drug is characterized by excellent compliance. KEYWORDS: polycystic ovary syndrome, drospirenone, body mass index, waist-hip ratio, reproductive age, ovary volume, glucose, insulin, carbohydrates, HOMA-IR. FOR CITATION: Saprykina L.V., Narimanova M.R., Ibragimova D.M. Effect of drospirenone-containing combined oral contraceptive pills on anthropometric and sonographic characteristics and carbohydrate metabolism parameters in women with polycystic ovary syndrome. Russian Journal of Woman and Child Health. 2022;5(2):118–121 (in Russ.). DOI: 10.32364/2618-8430-2022-5-2-118-121.\",\"PeriodicalId\":34075,\"journal\":{\"name\":\"RMZh Mat'' i ditia\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"RMZh Mat'' i ditia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.32364/2618-8430-2022-5-2-118-121\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"RMZh Mat'' i ditia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32364/2618-8430-2022-5-2-118-121","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:多囊卵巢综合征(PCOS)是一种影响10%育龄妇女的内分泌疾病。复方口服避孕药(COCP)对多囊卵巢综合征(PCOS)有效。屈螺酮是一种新型黄体酮,具有与天然黄体酮相似的特性(包括抗矿化皮质激素和抗雄激素活性)。目的:评价含屈螺酮COCP (20 μg炔雌醇加3 mg屈螺酮)对PCOS女性人体测量、超声特征及碳水化合物代谢参数的影响。患者和方法:本前瞻性研究纳入22名育龄妇女(平均年龄22.1±0.5岁)多囊卵巢综合征。所有的雌性在6个周期(每个28天)内治疗。在基线和开始治疗后6个月,评估人体测量(体重指数/BMI,腰臀比/WHR)和超声(卵巢体积)特征,以及碳水化合物代谢参数(血浆胰岛素,空腹血糖,胰岛素抵抗的稳态模型评估/HOMA-IR)。结果:开始治疗6个月后,血浆胰岛素浓度(9.91±0.42 μU/ml vs. 9.52±0.31 μU/ml)、空腹血糖(4.95±0.08 mmol/l vs. 4.9±0.07 mmol/l)、HOMA-IR(3.2±1.12 vs. 3.06±0.07)与基线水平相比有显著(p0.05)变化。最常见的副作用是头痛或头晕(n=3, 13.6%)、恶心(n=2, 9.1%)和不规则出血(n=3, 13.6%)。结论:含螺螺酮的COCP对人体测量参数和卵巢体积有有益影响,但不影响碳水化合物代谢。该药的特点是极好的顺应性。关键词:多囊卵巢综合征、降螺酮、体重指数、腰臀比、生育年龄、卵巢体积、葡萄糖、胰岛素、碳水化合物、HOMA-IR。引用本文:Saprykina l.v., Narimanova m.r., Ibragimova D.M.含多螺旋酮联合口服避孕药对多囊卵巢综合征女性人体测量、超声特征及碳水化合物代谢参数的影响。俄罗斯妇幼卫生杂志,2022;5(2):118-121。DOI: 10.32364 / 2618-8430-2022-5-2-118-121。
Effect of drospirenone-containing combined oral contraceptive pills on anthropometric and sonographic characteristics and carbohydrate metabolism parameters in women with polycystic ovary syndrome
Background: polycystic ovary syndrome (PCOS) is an endocrine disorder affecting 10% of women of reproductive age. Combined oral contraceptive pills (COCP) are effective in PCOS. Drospirenone is a new progestin with properties similar to natural progesterone (including anti-mineralocorticoid and antiandrogenic activities). Aim: to evaluate the effect of drospirenone-containing COCP (20 μg ethinylestradiol and 3 mg drospirenone) on anthropometric and sonographic characteristics, and carbohydrate metabolism parameters in women with PCOS. Patients and Methods: this prospective study enrolled 22 women of reproductive age (mean age 22.1±0.5 years) with PCOS. All females were treated during six cycles (28 days each). At baseline and 6 months after starting treatment, anthropometric (body mass index/BMI, waist-to- hip ratio/WHR) and sonographic (ovary volume) characteristics, and carbohydrate metabolism parameters (plasma insulin, fasting glucose, homeostasis model assessment of insulin resistance/HOMA-IR) were assessed. Results: 6 months after starting treatment, a significant (p<0.05) reduction in BMI (from 22.54±0.43 kg/m2 to 20.86±0.26 kg/m2), WHR (from 0.81±0.01 to 0.78±0.01), and ovary volume (left ovary: from 12.75±0.43 cm3 to 8.05±0.15 cm3; right ovary: from 13.0±0.54 cm3 to 8.63±0.14 cm3) was reported. Meanwhile, no significant (р>0.05) changes in plasma insulin concentration (9.91±0.42 μU/ml vs. 9.52±0.31 μU/ml), fasting blood glucose (4.95±0.08 mmol/l vs. 4.9±0.07 mmol/l), and HOMA-IR (3.2±1.12 vs. 3.06±0.07) compared to baseline levels were reported. The most common side effects were headache or dizziness (n=3, 13.6%), nausea (n=2, 9.1%) and irregular bleeding (n=3, 13.6%). Conclusion: drospirenone-containing COCP has a beneficial effect on anthropometric paramaters and ovary volume but does not affect carbohydrate metabolism. This drug is characterized by excellent compliance. KEYWORDS: polycystic ovary syndrome, drospirenone, body mass index, waist-hip ratio, reproductive age, ovary volume, glucose, insulin, carbohydrates, HOMA-IR. FOR CITATION: Saprykina L.V., Narimanova M.R., Ibragimova D.M. Effect of drospirenone-containing combined oral contraceptive pills on anthropometric and sonographic characteristics and carbohydrate metabolism parameters in women with polycystic ovary syndrome. Russian Journal of Woman and Child Health. 2022;5(2):118–121 (in Russ.). DOI: 10.32364/2618-8430-2022-5-2-118-121.